Could cause temporary or reversible harm; serious harm is unlikely.
Failed Impurities/Degradation Specification: presence of N-nitroso Prazosin impurity C above the Carcinogenic Potency Categorization Approach (CPCA) acceptable intake limit
| Brand name | PRAZOSIN HYDROCHLORIDE |
| Generic name | PRAZOSIN HYDROCHLORIDE |
| Active ingredient(s) | PRAZOSIN HYDROCHLORIDE |
| Distributed by / for | American Health Packaging, Columbus, Ohio 43217, carton |
| NDC | 60687-572-32 |
| Full product label | Prazosin Hydrochloride, Capsules, USP, 5 mg, 20 capsules (5x4) cartons, Rx only, Distributed by American Health Packaging, Columbus, Ohio 43217, carton NDC 60687-572-32, Individual unit dose: NDC 60687-572-33 |
| Recalling firm | Amerisource Health Services LLC |
| Distribution | Nationwide within the United States |
| Quantity | 3,410 cartons |
| Recall initiated | 2025-10-16 |
| Report date | 2025-11-05 |
| Recall completed | — |
| Recall number | D-0103-2026 |
| Classification | Class II |
| FDA status | Ongoing |
| Origin on file | Columbus OH United States |
Source: U.S. FDA enforcement database (openFDA). Look this up on the official FDA recalls site ↗